Tuesday, 15 November 2011

Research questions for dabigatran

Had a *cough* free sandwich from the Boerhinger rep at the Friday lunchtime meeting last week in Truro where some slides were presented on dabigatran (Pradaxa).

I've been using scoop.it to pull together a number of recent articles on dabigatran and await the final determination of NICE which is due in December.


There are some research questions for dabigatran in AF.

How best to encourage compliance? With warfarin the intensity of the monitoring and the importance placed on it by healthcare staff surely encourages compliance. With the twice daily dosing of dabigatran and the absence of monitoring it will not be as good.
Is there a higher risk of MI or acute coronary syndrome? This was reported in a meta-analysis for the AHA this year.
How does dabigatran compare with the other new anticoagulants? e.g. rivaroxaban

1 comment:

  1. On Dec. 7, 2011, the U.S. Food and Drug Administration (FDA) announced that it had began a formal investigation into the 260 reports of fatal Pradaxa® injuries that occurred from March 2008 to October 2011 (a period of approx. 3-1/2 years).

    Symptoms of bleeding, one of the many adverse Pradaxa® side effects preceded many of the deaths linked to this anticoagulant drug. The FDA said it will be conducting the investigation to determine if the incidence of bleeding and deaths among patients prescribed Pradaxa® is higher than what would be expected based on observations in the clinical trial that was held before the FDA approved Pradaxa® (dabigatran).